Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Clinical trial NCT03607890 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03607890
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy MSI-H Tumors

Start date: 2018-11-16
Primary completion: 2026-10-01
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.